(NASDAQ: DSGN) Design Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Design Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast DSGN's revenue for 2028 to be $2,260,931,461, with the lowest DSGN revenue forecast at $2,260,931,461, and the highest DSGN revenue forecast at $2,260,931,461. On average, 1 Wall Street analysts forecast DSGN's revenue for 2029 to be $1,352,717,214, with the lowest DSGN revenue forecast at $1,352,717,214, and the highest DSGN revenue forecast at $1,352,717,214.
In 2030, DSGN is forecast to generate $4,444,295,233 in revenue, with the lowest revenue forecast at $4,444,295,233 and the highest revenue forecast at $4,444,295,233.